Dual sensing activates antiviral reverse transcriptase for membrane targeting
Cell Host & Microbe · 2026-10 · 34 (10) · 2014-2027.e6
DOI: 10.1016/j.chom.2026.08.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Host & Microbe, 2026-10. Verfasst von Yushan Xia und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, SUSTech Homeostatic Medicine Institute, School of Medicine, Southern University of Science and Technology, Shenzhen 51805…. Hauptthemen laut MEDLINE: RNA-Directed DNA Polymerase, Cell Membrane. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Major Projects of Basic and Applied Basic Research of Guangdong Province, National Natural Science Foundation of China, Shenzhen Science and Technology Innovation Program.
Abstract (Originalsprache)
The prokaryotic type 2 defense-associated reverse transcriptase (DRT2) system mediates antiviral defense by catalyzing the rolling-circle reverse transcription of a noncoding RNA (ncRNA) and producing the toxic Neo protein that arrests bacterial growth. However, the mechanisms underlying DRT2 activation and effector function remain unknown. Here, we identified two distinct activation mechanisms: direct binding of a phage-encoded single-stranded DNA-binding protein (SSB or SSAP), and the detection of elevated intracellular dGTP levels induced by the phage-encoded ribonucleotide reductase NrdAB. Upon activation, the produced Neo protein directly targets the bacterial membrane, inducing membrane depolarization and growth arrest. Cryo-electron microscopy (cryo-EM) structures of the DRT2-ncRNA complex in its arrested and dGTP-bound active states provide mechanistic insights into rolling-circle ccDNA synthesis and template jumping. Furthermore, these identified activation mechanisms enable the DRT2 system with an engineered ncRNA template to produce a large-scale, user-defined double-stranded DNA (dsDNA) template in vivo, highlighting its potential in biotechnological applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, SUSTech Homeostatic Medicine Institute, School of Medicine, Southern University of Science and Technology, Shenzhen 518055, China.
- Guangdong Provincial Key Laboratory of Infection Immunity and Inflammation, Department of Pathogen Biology, International Cancer Center, Shenzhen University Medical School, Shenzhen 518055, Guangdong, China.
- Center for Human Tissues and Organs Degeneration, Shenzhen Key Laboratory of Biomimetic Materials and Cellular Immunomodulation, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 581055,…
- Department of Biochemistry, SUSTech Homeostatic Medicine Institute, School of Medicine, Southern University of Science and Technology, Shenzhen 518055, China; Shenzhen Key Laboratory of Cell Microenvironment, Key Univer…
Förderung
- Major Projects of Basic and Applied Basic Research of Guangdong Province
- National Natural Science Foundation of China
- Shenzhen Science and Technology Innovation Program
- Guangdong Provincial Natural Science Foundation
Zitieren
APA
Xia, Y., Qi, H., Wei, X. Y., Zhang, J. T., Hu, W., Liu, Y. J., Song, X. Y., Liu, X., Wang, C., & Jia, N. (2026). Dual sensing activates antiviral reverse transcriptase for membrane targeting. Cell Host & Microbe, 34(10), 2014-2027.e6. https://doi.org/10.1016/j.chom.2026.08.006
Vancouver
Xia Y, Qi H, Wei XY, Zhang JT, Hu W, Liu YJ, et al. Dual sensing activates antiviral reverse transcriptase for membrane targeting. Cell Host & Microbe. 2026;34(10):2014-2027.e6. doi:10.1016/j.chom.2026.08.006
BibTeX
@article{Xia2026,
author = {Xia, Yushan and Qi, Hua and Wei, Xin-Yang and Zhang, Jun-Tao and Hu, Wenao and Liu, Yu-Jun and Song, Xin-Yi and Liu, Xue and Wang, Chongyuan and Jia, Ning},
title = {Dual sensing activates antiviral reverse transcriptase for membrane targeting},
journal = {Cell Host & Microbe},
year = {2026},
volume = {34},
number = {10},
pages = {2014--2027.e6},
doi = {10.1016/j.chom.2026.08.006}
}
EUVIMED